Ocrevus, also known as ocrelizumab, is a treatment used for certain forms of multiple sclerosis. Because it affects B cells involved in the immune system, ongoing follow up is an important part of treatment management. The current prescribing information recommends monitoring for infections, changes in immunoglobulin levels, liver injury, and other potential safety concerns.
Understanding Ocrevus Follow Up Assessments
Follow up appointments allow healthcare professionals to review how a person is doing since treatment and identify concerns that may require further evaluation. The frequency and type of monitoring can differ depending on the person's medical history, symptoms, and clinical situation.
Common areas that may be reviewed include:
- Multiple sclerosis symptoms: Neurological symptoms and changes in function may be discussed to assess disease activity and progression.
- Laboratory testing: Before treatment, testing includes hepatitis B screening, quantitative immunoglobulins, and liver-related blood tests. Additional testing may be performed during treatment when clinically appropriate.
- Infection assessment: Ocrevus can increase susceptibility to certain infections. New or persistent symptoms such as fever, cough, or other signs of infection should be reported to a healthcare professional.
- Immunoglobulin monitoring: Ocrevus can reduce immunoglobulin levels, so healthcare professionals may monitor these levels during treatment and after discontinuation until B-cell recovery, particularly when serious or repeated infections occur.
Important Safety Monitoring During Treatment
Monitoring also helps healthcare professionals identify adverse reactions and decide whether treatment should be delayed, adjusted, or otherwise managed. Ocrevus is generally administered at six-month intervals after the initial dosing schedule, although individual treatment decisions should be made by the treating healthcare professional.
Important safety considerations include:
- Infusion reactions: Patients receiving intravenous Ocrevus are monitored during the infusion and for at least one hour afterward. Reactions can also occur after leaving the treatment setting.
- Liver function: Liver enzymes and bilirubin may be assessed before treatment and during treatment when clinically indicated. New symptoms that could suggest liver injury require prompt medical evaluation.
- Hepatitis B: Screening is recommended before starting treatment because hepatitis B reactivation can occur in people with previous infection. At-risk individuals may require additional monitoring.
- Neurological changes: New or worsening neurological symptoms should be reported promptly because rare conditions such as progressive multifocal leukoencephalopathy have been reported with ocrelizumab.
Regular follow up provides an opportunity to evaluate both treatment safety and multiple sclerosis activity. Monitoring requirements are individualized, so patients should follow the schedule and testing recommendations provided by their healthcare professional. This information is educational and is not a substitute for medical advice, diagnosis, or treatment.